Promising drug targets rare bone disease in kids
NCT ID NCT07559513
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This study tests an experimental drug called garetosmab in children and teens with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal is to see if the drug is safe and can reduce new abnormal bone growth and flare-ups. About 18 participants aged 2 to 17 will receive the drug, and researchers will monitor side effects, drug levels, and disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.